{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:11:36Z","timestamp":1790709096234,"version":"4.1.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"6","funder":[{"name":"Defense Health Agency Immunization Healthcare Division","award":["# IHBG-15-05"],"award-info":[{"award-number":["# IHBG-15-05"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Yellow fever (YF) is a rare viral disease that can be prevented through receipt of a live attenuated vaccine. In the US military, service members must receive the YF vaccine before assignment to endemic areas, putting active duty service women at heightened risk for inadvertent exposure during preconception or pregnancy. Few studies have investigated the safety of YF vaccination in pregnancy to date, and none in a military population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Department of Defense Birth and Infant Health Research program data were used to identify pregnancies and infants among active duty US military women, 2003\u20132014. Multivariable regression models estimated associations with YF vaccine exposure during preconception\/pregnancy and adverse outcomes (e.g. spontaneous abortion, birth defects). Sensitivity analyses were performed that excluded pregnancies exposed to other live vaccines. For analyses of birth defects only, a secondary sensitivity analysis was performed that excluded infants diagnosed with chromosomal anomalies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the 196\u2009802 pregnancies and 160\u2009706 singleton infants identified, 1347 (0.7%) and 1132 (0.7%), respectively, were exposed to the YF vaccine. No increased risks for adverse pregnancy or infant outcomes were observed in the main analysis. In sensitivity analyses that excluded pregnancies exposed to other live vaccines, preconception YF vaccine exposure was associated with birth defects [adjusted risk ratio (aRR)\u2009=\u20091.71, 95% confidence interval (CI)\u2009=\u20091.08\u20132.73]; this association was attenuated when further excluding infants with chromosomal anomalies (aRR\u2009=\u20091.59, 95% CI\u2009=\u20090.97\u20132.62).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Overall, YF vaccine exposure did not appear to be associated with most adverse outcomes among this population of pregnant military women. A tenuous association between preconception YF vaccine exposure and birth defects was observed in sensitivity analyses, which may warrant further investigation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jtm\/taaa138","type":"journal-article","created":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T19:08:57Z","timestamp":1597950537000},"source":"Crossref","is-referenced-by-count":18,"title":["Safety of yellow fever vaccination in pregnancy: findings from a cohort of active duty US military women"],"prefix":"10.1093","volume":"27","author":[{"given":"Clinton","family":"Hall","sequence":"first","affiliation":[{"name":"Leidos, Inc., 140 Sylvester Road, San Diego, CA, USA"},{"name":"Deployment Health Research Department, Naval Health Research Center, 140 Sylvester Road, San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeina G","family":"Khodr","sequence":"additional","affiliation":[{"name":"Leidos, Inc., 140 Sylvester Road, San Diego, CA, USA"},{"name":"Deployment Health Research Department, Naval Health Research Center, 140 Sylvester Road, San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard N","family":"Chang","sequence":"additional","affiliation":[{"name":"Leidos, Inc., 140 Sylvester Road, San Diego, CA, USA"},{"name":"Deployment Health Research Department, Naval Health Research Center, 140 Sylvester Road, San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna T","family":"Bukowinski","sequence":"additional","affiliation":[{"name":"Leidos, Inc., 140 Sylvester Road, San Diego, CA, USA"},{"name":"Deployment Health Research Department, Naval Health Research Center, 140 Sylvester Road, San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gia R","family":"Gumbs","sequence":"additional","affiliation":[{"name":"Leidos, Inc., 140 Sylvester Road, San Diego, CA, USA"},{"name":"Deployment Health Research Department, Naval Health Research Center, 140 Sylvester Road, San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ava Marie S","family":"Conlin","sequence":"additional","affiliation":[{"name":"Deployment Health Research Department, Naval Health Research Center, 140 Sylvester Road, San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,8,24]]},"reference":[{"key":"2020092804150268000_ref1","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1001\/jama.300.8.960","article-title":"Yellow fever: 100 years of discovery","volume":"300","author":"Staples","year":"2008","journal-title":"JAMA"},{"key":"2020092804150268000_ref2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jtm\/tax008","article-title":"Importation of yellow fever into China: assessing travel patterns","volume":"24","author":"Wilder-Smith","year":"2017","journal-title":"J Travel Med"},{"key":"2020092804150268000_ref3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jtm\/tay097","article-title":"Pandemic yellow fever: a potential threat to global health via travelers","volume":"25","author":"Gubler","year":"2018","journal-title":"J Travel Med"},{"key":"2020092804150268000_ref4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jtm\/taz040","article-title":"Severe yellow fever in Brazil: clinical characteristics and management","volume":"26","author":"Ho","year":"2019","journal-title":"J Travel Med"},{"key":"2020092804150268000_ref5","volume-title":"Global Health Situation and Projections Estimates","author":"World Health Organization, Division of Epidemiological Surveillance and Health Situation and Trend Assessment","year":"1992"},{"key":"2020092804150268000_ref6","volume-title":"Product Approval Information [package insert]. YF-VAX (Yellow Fever Vaccine)","author":"Food and Drug Administration"},{"key":"2020092804150268000_ref7","volume-title":"Lifetime Validity of One Dose of Yellow Fever Vaccine: Amendment to Annex 7 of IHR (2005)","author":"Worth Health Organization","year":"2014"},{"key":"2020092804150268000_ref8","first-page":"647","article-title":"Yellow fever vaccine booster doses: recommendations of the Advisory Committee on Immunization Practices, 2015","volume":"64","author":"Staples","year":"2015","journal-title":"MMWR"},{"key":"2020092804150268000_ref9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jtm\/taw045","article-title":"Adverse event reports following yellow fever vaccination, 2007-13","volume":"23","author":"Lindsey","year":"2016","journal-title":"J Travel Med"},{"key":"2020092804150268000_ref10","doi-asserted-by":"crossref","first-page":"4544","DOI":"10.1016\/j.vaccine.2011.04.055","article-title":"Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review","volume":"29","author":"Thomas","year":"2011","journal-title":"Vaccine"},{"key":"2020092804150268000_ref11","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.2147\/DDDT.S99600","article-title":"Yellow fever vaccine-associated viscerotropic disease: current perspectives","volume":"10","author":"Thomas","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"2020092804150268000_ref12","doi-asserted-by":"crossref","first-page":"945","DOI":"10.3201\/eid0706.010605","article-title":"Advanced age a risk factor for illness temporally associated with yellow fever vaccination","volume":"7","author":"Martin","year":"2001","journal-title":"Emerg Infect Dis"},{"key":"2020092804150268000_ref13","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1177\/2051013613498954","article-title":"Advances and controversies in yellow fever vaccination","volume":"1","author":"Jonker","year":"2013","journal-title":"Ther Adv Vaccines"},{"key":"2020092804150268000_ref14","doi-asserted-by":"crossref","first-page":"e674","DOI":"10.1542\/peds.2013-3205","article-title":"Systematic review and meta-analyses: fever in pregnancy and health impacts in the offspring","volume":"133","author":"Dreier","year":"2014","journal-title":"Pediatrics"},{"key":"2020092804150268000_ref15","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1093\/infdis\/168.6.1520","article-title":"Congenital yellow fever virus infection after immunization in pregnancy","volume":"168","author":"Tsai","year":"1993","journal-title":"J Infect Dis"},{"key":"2020092804150268000_ref16","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.3201\/eid1709.110242","article-title":"Perinatal transmission of yellow fever, Brazil, 2009","volume":"17","author":"Bentlin","year":"2011","journal-title":"Emerg Infect Dis"},{"key":"2020092804150268000_ref17","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ntt.2012.12.002","article-title":"Gestational exposure to yellow fever vaccine at different developmental stages induces behavioral alterations in the progeny","volume":"35","author":"Marianno","year":"2013","journal-title":"Neurotoxicol Teratol"},{"key":"2020092804150268000_ref18","first-page":"1","article-title":"Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"59","author":"Staples","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"2020092804150268000_ref19","volume-title":"International Travel and Health: Yellow Fever","author":"World Health Organizaiton"},{"key":"2020092804150268000_ref20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14745\/ccdr.v36i00a02","article-title":"Statement on pregnancy and travel: committee to advise on tropical medicine and travel","volume":"36","author":"Beallor","year":"2010","journal-title":"Can Commun Dis Rep"},{"key":"2020092804150268000_ref21","first-page":"1","article-title":"Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002","volume":"51","author":"Cetron","year":"2002","journal-title":"MMWR Recomm Rep"},{"key":"2020092804150268000_ref22","first-page":"39","article-title":"Department of Defense Birth and Infant Health Registry: select reproductive health outcomes, 2003-2014","volume":"24","author":"Bukowinski","year":"2017","journal-title":"MSMR"},{"key":"2020092804150268000_ref23","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/AOG.0b013e318280d64e","article-title":"Safety of the pandemic H1N1 influenza vaccine among pregnant U.S. military women and their newborns","volume":"121","author":"Conlin","year":"2013","journal-title":"Obstet Gynecol"},{"key":"2020092804150268000_ref24","doi-asserted-by":"crossref","first-page":"101519","DOI":"10.1016\/j.tmaid.2019.101519","article-title":"Atovaquone-proguanil exposure in pregnancy and risk for adverse fetal and infant outcomes: a retrospective analysis","volume":"17","author":"Gutman","year":"2019","journal-title":"Travel Med Infect Dis"},{"key":"2020092804150268000_ref25","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/pds.4153","article-title":"Identifying birth defects in automated data sources in the vaccine safety Datalink","volume":"26","author":"Kharbanda","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2020092804150268000_ref26","volume-title":"Guidelines for Conducting Birth Defects Surveillance","author":"National Birth Defects Prevention Network (NBDPN)","year":"2004"},{"key":"2020092804150268000_ref27","doi-asserted-by":"crossref","first-page":"359","DOI":"10.4269\/ajtmh.2012.11-0525","article-title":"The safety of yellow fever vaccine 17D or 17DD in children, pregnant women, HIV+ individuals, and older persons: systematic review","volume":"86","author":"Thomas","year":"2012","journal-title":"Am J Trop Med Hyg"},{"key":"2020092804150268000_ref28","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.vaccine.2005.09.033","article-title":"The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil","volume":"24","author":"Suzano","year":"2006","journal-title":"Vaccine"},{"key":"2020092804150268000_ref29","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0264-410X(98)00051-6","article-title":"Exposure to yellow fever vaccine in early pregnancy","volume":"17","author":"Robert","year":"1999","journal-title":"Vaccine"},{"key":"2020092804150268000_ref30","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0035-9203(93)90156-K","article-title":"Yellow fever vaccination and pregnancy: a four-year prospective study","volume":"87","author":"Nasidi","year":"1993","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2020092804150268000_ref31","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/j.1365-3156.2007.01851.x","article-title":"Early exposure to yellow fever vaccine during pregnancy","volume":"12","author":"Cavalcanti","year":"2007","journal-title":"Trop Med Int Health"},{"key":"2020092804150268000_ref32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1046\/j.1365-3156.1998.00164.x","article-title":"Yellow fever vaccination during pregnancy and spontaneous abortion: a case-control study","volume":"3","author":"Nishioka Sde","year":"1998","journal-title":"Trop Med Int Health"},{"key":"2020092804150268000_ref33","first-page":"69","article-title":"Validating the use of ICD-9-CM codes to evaluate gestational age and birth weight","volume":"39","author":"Barrett","year":"2012","journal-title":"J Registry Manag"},{"key":"2020092804150268000_ref34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jtm\/tay108","article-title":"Persistence of yellow fever virus-specific neutralizing antibodies after vaccination among US travellers","volume":"25","author":"Lindsey","year":"2018","journal-title":"J Travel Med"}],"container-title":["Journal of Travel Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jtm\/advance-article-pdf\/doi\/10.1093\/jtm\/taaa138\/33780638\/taaa138.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jtm\/article-pdf\/27\/6\/taaa138\/33794551\/taaa138.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jtm\/article-pdf\/27\/6\/taaa138\/33794551\/taaa138.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T08:15:34Z","timestamp":1601280934000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jtm\/article\/doi\/10.1093\/jtm\/taaa138\/5896042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":34,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,8,24]]},"published-print":{"date-parts":[[2020,9,26]]}},"URL":"https:\/\/doi.org\/10.1093\/jtm\/taaa138","relation":{},"ISSN":["1195-1982","1708-8305"],"issn-type":[{"value":"1195-1982","type":"print"},{"value":"1708-8305","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,8]]},"published":{"date-parts":[[2020,8]]},"article-number":"taaa138"}}